Loading clinical trials...
Loading clinical trials...
A Pilot Study Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo in the Treatment of Moderate-to-severe Hidradenitis Suppurativa (HS).
Conditions
Interventions
Deucravacitinib
Placebo
Locations
1
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Start Date
November 30, 2023
Primary Completion Date
February 25, 2025
Completion Date
April 10, 2025
Last Updated
May 7, 2025
NCT06993233
NCT06888193
NCT07316192
NCT06768671
NCT06517732
NCT07228390
Lead Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions